Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. Our product, Cloretazine® (VNP40101M) is currently being studied for the treatment of acute myelogenous leukemia (AML), including a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition a trial of Cloretazine® (VNP40101M) is underway in small cell lung cancer. Our second clinical-stage product, Triapine®, is being evaluated in several trials sponsored by the National Cancer Institute. Additional small molecule anticancer compounds are under development in preclinical studies.